The Chemours Company filings document formal disclosures for a NYSE-listed global chemistry company with businesses in Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials. Recent Form 8-K reports furnish operating results and financial condition updates, including segment commentary on Opteon refrigerants, TiO2 pigment, and other specialty-chemistry markets.
Regulatory filings also cover capital-structure actions, including senior unsecured notes, indentures, guarantees, and redemption of outstanding debt. Definitive proxy materials document board structure, director elections, advisory compensation votes, auditor ratification, equity-incentive plan approval, and other shareholder voting matters.
Chemours Co Chief Accounting Officer David Will reported an equity award and a related tax withholding transaction. He received a grant covering 8,337 shares of common stock at no cost, structured as an RSU award scheduled to vest in three equal annual installments beginning on March 1, 2027. In a separate transaction, 699 shares were automatically withheld at $18.24 per share to satisfy tax obligations on vesting restricted stock units and dividend equivalent units; the footnote states that no shares were sold in the market. Following these transactions, his directly owned holdings, including RSUs and dividend equivalent units, total 33,083.5415 shares.
Chemours Co senior vice president and general counsel Kristine M. Wellman reported routine equity compensation transactions in company common stock. She acquired 1,781 shares at no cost through performance stock units granted under the Long Term Incentive Plan, which vested after the compensation committee certified performance conditions were met.
To cover related tax obligations on vesting restricted stock units and dividend equivalent units, 675 shares were automatically withheld at a price of $18.41 per share; the footnotes state no shares were sold on the market. After these transactions and an adjustment correcting a prior administrative error, her directly owned, restricted stock unit, and dividend equivalent unit holdings total 51,401.6057 shares.
Chemours Co Chief Executive Officer Denise Dignam received 2,261 shares of common stock as a performance-based stock award tied to 2023 compensation, issued at no cash cost to her after performance conditions were certified. To cover taxes on vesting, 742 shares were automatically withheld at $18.4100 per share, and the footnotes state that no shares were sold. Following these transactions and an adjustment for a prior administrative error, her directly owned and related holdings total 187,995.8721 shares, including restricted stock units and dividend equivalent units.
The Chemours Company filed a Form 8-K to report a private debt financing. The company launched and priced an upsized offering of $700,000,000 aggregate principal amount of 7.875% senior unsecured notes due 2034, increased from a previously announced $600,000,000 offering size.
The notes mature on March 15, 2034 and will pay interest semi-annually on March 15 and September 15, starting September 15, 2026. Chemours intends to use the net proceeds to redeem its outstanding 5.375% senior notes due 2027 and partially redeem its outstanding 5.750% senior notes due 2028. The notes are being sold in a private offering to qualified institutional buyers under Rule 144A and to certain non-U.S. investors under Regulation S.
The Chemours Company provides a detailed annual overview of its business, strategy, and key risks. The company operates three main segments: Thermal & Specialized Solutions (refrigerants and thermal management), Titanium Technologies (TiO₂ pigments), and Advanced Performance Materials (high‑end fluoropolymers and specialty materials).
Chemours’ “Pathway to Thrive” strategy focuses on operational excellence, targeted growth in areas like data center cooling, next‑generation refrigerants, and semiconductors, active portfolio management, and addressing legacy litigation and environmental matters. A major Titanium Technologies transformation included shutting its Kuan Yin, Taiwan TiO₂ plant, generating cost savings and leading to land sale agreements of about $360 million, with proceeds intended to reduce debt.
The company emphasizes sustainability, targeting a 60% reduction in Scope 1 and 2 greenhouse gas emissions and a 25% reduction in Scope 3 intensity by 2030, with a long‑term goal of net zero by 2050. It highlights significant environmental, regulatory, PFAS‑related, and litigation exposures, as well as dependence on global economic conditions, raw material costs, and robust safety and human‑capital management for long‑term performance.
The Chemours Company reported fourth quarter 2025 net sales of $1.3 billion, down 2% year over year, and a net loss of $47 million, or $0.31 per diluted share. Adjusted EBITDA was $128 million versus $168 million a year earlier.
For full year 2025, net sales were $5.8 billion, essentially flat, but results swung to a net loss of $386 million, or $2.57 per share, from net income of $69 million, largely due to litigation-related and environmental charges. Adjusted EBITDA slipped modestly to $742 million from $768 million. TSS delivered record net sales of $2.1 billion and Adjusted EBITDA of $670 million, while TT and APM saw sharp profit declines. Net debt was $3.5 billion with a 4.7x net leverage ratio. For 2026, Chemours guides to 3–5% net sales growth, Adjusted EBITDA of $800–$900 million, and Free Cash Flow Conversion above 25%.
Chemours Co officer Michael Robert Foley filed an initial statement of beneficial ownership as of February 4, 2026. He reported holding 3,500 shares of Chemours common stock in direct ownership. Foley is identified with the title President, Titanium Technologies, and no derivative securities were listed.
The Chemours Company agreed to sell ten parcels of land in Kuan Yin, Taiwan, for a total purchase price of approximately $360 million. The sale is being executed through four real estate sale and purchase agreements between a Chemours subsidiary and four affiliated buyers, and the company plans to use the cash proceeds to reduce its debt obligations.
The transaction is expected to close in one or more stages by mid-year 2026, subject to closing conditions and local regulatory approvals, including environmental conditions. The agreements include customary representations, warranties, covenants, indemnities, and termination provisions for industrial property deals, and were negotiated on an arm’s-length basis with no other material relationships between Chemours and the buyers. Chemours also issued a press release outlining the property sale.
Chemours Co director reports new deferred stock units. A member of the board received 1,298 deferred stock units on 12/31/2025. Each unit is the economic equivalent of one share of Chemours common stock at a reference price of $11.79. These deferred stock units, together with related dividend equivalent units, will be paid in the second calendar year after the director’s service on the board ends. Following this grant, the director beneficially owns 4,615.309 derivative securities in the form of deferred stock units, held directly.
Chemours Company director reports deferred stock units grant
A director of Chemours Company reported receiving 2,226 deferred stock units on 12/31/2025. Each deferred stock unit is the economic equivalent of one share of Chemours common stock and becomes payable in the first month after the director’s termination of service. The transaction price is listed as $11.79 per unit. Following this grant, the reporting person beneficially owns a total of 6,216.3946 deferred stock units, which include both deferred stock units and related dividend equivalent units, all held in direct ownership.